1. Home
  2. NREF vs SGMT Comparison

NREF vs SGMT Comparison

Compare NREF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NREF
  • SGMT
  • Stock Information
  • Founded
  • NREF 2019
  • SGMT 2006
  • Country
  • NREF United States
  • SGMT United States
  • Employees
  • NREF N/A
  • SGMT N/A
  • Industry
  • NREF Real Estate Investment Trusts
  • SGMT
  • Sector
  • NREF Real Estate
  • SGMT
  • Exchange
  • NREF Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • NREF 250.2M
  • SGMT 238.7M
  • IPO Year
  • NREF 2020
  • SGMT 2023
  • Fundamental
  • Price
  • NREF $13.37
  • SGMT $7.79
  • Analyst Decision
  • NREF Hold
  • SGMT Strong Buy
  • Analyst Count
  • NREF 3
  • SGMT 7
  • Target Price
  • NREF $14.75
  • SGMT $26.57
  • AVG Volume (30 Days)
  • NREF 47.0K
  • SGMT 487.6K
  • Earning Date
  • NREF 10-30-2025
  • SGMT 11-12-2025
  • Dividend Yield
  • NREF 14.94%
  • SGMT N/A
  • EPS Growth
  • NREF N/A
  • SGMT N/A
  • EPS
  • NREF 2.59
  • SGMT N/A
  • Revenue
  • NREF $121,573,000.00
  • SGMT N/A
  • Revenue This Year
  • NREF $27.27
  • SGMT N/A
  • Revenue Next Year
  • NREF $5.40
  • SGMT N/A
  • P/E Ratio
  • NREF $5.17
  • SGMT N/A
  • Revenue Growth
  • NREF 302.49
  • SGMT N/A
  • 52 Week Low
  • NREF $12.14
  • SGMT $1.73
  • 52 Week High
  • NREF $18.09
  • SGMT $11.41
  • Technical
  • Relative Strength Index (RSI)
  • NREF 37.41
  • SGMT 54.57
  • Support Level
  • NREF $13.31
  • SGMT $7.15
  • Resistance Level
  • NREF $13.83
  • SGMT $7.97
  • Average True Range (ATR)
  • NREF 0.31
  • SGMT 0.56
  • MACD
  • NREF -0.02
  • SGMT 0.05
  • Stochastic Oscillator
  • NREF 12.96
  • SGMT 47.57

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: